Metagenomi, Inc. Common Stock (MGX) compared with its closest peers (CSBR, EXOZ, INMB, IMA, INKT). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Champions Oncology, Inc. (CSBR) | $70.30M | 17.6 |
| eXoZymes, Inc. (EXOZ) | $68.45M | -9.7 |
| INmune Bio, Inc. (INMB) | $63.83M | -0.8 |
| ImageneBio Inc (IMA) | $63.34M | -0.7 |
| MiNK Therapeutics, Inc. (INKT) | $62.21M | -3.8 |
| Instil Bio, Inc. (TIL) | $51.81M | -1.0 |
| Scilex Holding Company (SCLX) | $48.07M | -0.3 |
| Aligos Therapeutics, Inc. (ALGS) | $41.03M | -3.8 |
| Elutia Inc. (ELUT) | $37.98M | 0.8 |
| Quince Therapeutics, Inc. (QNCX) | $33.82M | -2.0 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
MGX overview · MGX earnings · MGX financials · MGX KPIs · MGX investor relations · MGX ownership · MGX filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.